The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Wolfspeed (WOLF) delivered earnings and revenue surprises of 5.94% and 0.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback